Alrizomadlin by Ascentage Pharma Group International for Lung Adenocarcinoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Alrizomadlin overview

Alrizomadlin (APG-115) is under development for the treatment of solid tumors, neuroblastoma, relapsed/refractory T-cell prolymphocytic leukemia, soft tissue sarcoma, adenoid cystic carcinoma, uveal melanoma, osteosarcoma, liposarcoma, salivary gland cancer, relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, relapsed/ refractory chronic myelomonocytic leukemia (CMML), peripheral nerve sheath tumor, acute myelocytic leukemia (AML), STK11 mutated metastatic lung adenocarcinoma, gastric cancer, metastatic melanoma, retinoblastoma and neuroblastoma in children. It is administered through oral route. The drug candidate is a new chemical entity. It acts by targeting MDM2-p53. It is a small-molecule mouse double minute 2 homolog (MDM2) inhibitor.

The drug candidate was also under development for the treatment of dry age related macular degeneration, adenoid cystic carcinoma (ACC), sarcoma, lymphomas, STK11 mutated non-small cell lung cancer and urothelial cancer.

Ascentage Pharma Group International overview

Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It develops therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Alrizomadlin’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.